ATHE ALTERITY THERAPEUTICS LIMITED

Price Chart

Executive Summary

Alterity Therapeutics announced a successful End-of-Phase 2 meeting with the FDA, achieving alignment on the pivotal Phase 3 trial design for ATH434 in Multiple System Atrophy (MSA). The FDA agreed on the study population, dosing regimen (50 mg twice daily), primary endpoint (11-item UMSARS I), and statistical methods, de-risking the registrational pathway. Phase 3 trial initiation is on track for year-end 2026, with ATH434 having previously received Fast Track and Orphan Drug Designations.

Actionable Insight

Key Facts

• Successful End-of-Phase 2 meeting with FDA; alignment on Phase 3 design, including study population, dosing (50 mg BID), primary endpoint (11-item UMSARS I), and statistical methods.
• Phase 2 data showed ATH434 50 mg achieved 48% slowing of disease progression vs placebo on the primary endpoint.
• FDA agreed key secondary endpoints (Swallowing Disturbance Questionnaire, Orthostatic Hypotension Symptom Assessment, Clinical Global Impression of Severity) are suitable.
• Phase 3 trial planned as randomized, double-blind, placebo-controlled, ~200 patients, 1:1 ratio, 12-month treatment.
• ATH434 has Fast Track and Orphan Drug Designations from FDA for MSA.
• Phase 3 trial activities on track to initiate by year-end 2026.

Financial Impact

No financial figures disclosed; market cap ~$60M; successful Phase 3 outcome could transform valuation given MSA's high unmet need and no approved therapy.

Risk Factors

• Phase 3 trial may fail to meet primary or key secondary endpoints despite Phase 2 success.
• Company may need additional capital to complete Phase 3, leading to dilution.
• Regulatory approval is not guaranteed; FDA could require additional data or studies.
• Competing therapies in development for MSA could emerge.

Market Snapshot

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status